Astrocyte cell-surface proteomics identified CD44 as an OPN/SPP1 receptor regulating lipid metabolism and glial crosstalk in Alzheimer s disease
Authors:
- Omar Pena-RamosOPOmar Pena-Ramos
- Manasee GedamMGManasee Gedam
- Xue ZhangXZXue Zhang
- Shuo WangSWShuo Wang
- Chuangye QiCQChuangye Qi
- Tzu-Hsuan HuangTHTzu-Hsuan Huang
- Chetan RajpurohitCRChetan Rajpurohit
- Mikayla DunlapMDMikayla Dunlap
- Yu DengYDYu Deng
- Nicole AuldNANicole Auld
- Sung Yun JungSJSung Yun Jung
- Hongjie LiHLHongjie Li
Preprint
Abstract
The development of β-amyloid (Aβ) pathology in Alzheimer s disease (AD) is accompanied by profound changes in astrocytes and microglia. How these responses are orchestrated by cell surface proteins, key mediators of cell-cell communication, remain unclear. Using in situ astrocyte cell-surface proteome profiling in 5xFAD mice, we identified a set of dysregulated surface proteins induced by Aβ pathology, including CD44. CD44 was selectively upregulated in plaque-adjacent astrocytes and interacted with osteopontin (OPN), encoded by the diseaseassociated microglia gene Spp1, to promote lipid accumulation, and this effect is γ-secretase dependent. Astrocytic CD44 in turn regulated Spp1 expression and microglial activity. Conditional deletion of Cd44 in adult astrocytes of 5xFAD mice attenuated glial reactivity, reduced Aβ pathology, and improved cognition. These findings define a plaque-proximal OPN-CD44 axis that controls astrocyte lipid metabolism and glial activity, positioning CD44 as a surface-accessible therapeutic target in AD.Keywords
Funding Information
- NIA (R01 NS093652, R01 AG020670, P01 AG066606, RF1 AG088197)